FRA:COP • DE000A288904
We assign a fundamental rating of 3 out of 10 to COP. COP was compared to 11 industry peers in the Health Care Technology industry. There are concerns on the financial health of COP while its profitability can be described as average. COP has a correct valuation and a medium growth rate.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.34% | ||
| ROE | 4.15% | ||
| ROIC | 3.53% |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 8.13% | ||
| PM (TTM) | 2.34% | ||
| GM | 83.85% |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.22 | ||
| Debt/FCF | 9.74 | ||
| Altman-Z | 1.79 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.12 | ||
| Quick Ratio | 1.09 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 43.58 | ||
| Fwd PE | 12.88 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 14.34 | ||
| EV/EBITDA | 9.24 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.22% |
FRA:COP (6/24/2025, 7:00:00 PM)
22.66
+0.24 (+1.07%)
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.22% |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 43.58 | ||
| Fwd PE | 12.88 | ||
| P/S | 1.05 | ||
| P/FCF | 14.34 | ||
| P/OCF | 8.46 | ||
| P/B | 1.87 | ||
| P/tB | N/A | ||
| EV/EBITDA | 9.24 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.34% | ||
| ROE | 4.15% | ||
| ROCE | 5.85% | ||
| ROIC | 3.53% | ||
| ROICexc | 3.83% | ||
| ROICexgc | 41.76% | ||
| OM | 8.13% | ||
| PM (TTM) | 2.34% | ||
| GM | 83.85% | ||
| FCFM | 7.35% |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.22 | ||
| Debt/FCF | 9.74 | ||
| Debt/EBITDA | 3.86 | ||
| Cap/Depr | 52.61% | ||
| Cap/Sales | 5.11% | ||
| Interest Coverage | 2.54 | ||
| Cash Conversion | 69.81% | ||
| Profit Quality | 314.42% | ||
| Current Ratio | 1.12 | ||
| Quick Ratio | 1.09 | ||
| Altman-Z | 1.79 |
ChartMill assigns a fundamental rating of 3 / 10 to COP.DE.
ChartMill assigns a valuation rating of 3 / 10 to COMPUGROUP MEDICAL SE & CO K (COP.DE). This can be considered as Overvalued.
COMPUGROUP MEDICAL SE & CO K (COP.DE) has a profitability rating of 4 / 10.
The Earnings per Share (EPS) of COMPUGROUP MEDICAL SE & CO K (COP.DE) is expected to grow by 1.4% in the next year.
The dividend rating of COMPUGROUP MEDICAL SE & CO K (COP.DE) is 2 / 10 and the dividend payout ratio is 191.63%.